Diamond Hill Capital Management Inc. grew its holdings in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 32.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 211,038 shares of the company's stock after acquiring an additional 51,827 shares during the period. Diamond Hill Capital Management Inc. owned about 0.38% of Astrana Health worth $6,544,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the business. Swiss National Bank grew its stake in Astrana Health by 1.1% in the fourth quarter. Swiss National Bank now owns 88,444 shares of the company's stock worth $2,789,000 after purchasing an additional 1,000 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in Astrana Health by 415.3% in the fourth quarter. Teacher Retirement System of Texas now owns 81,207 shares of the company's stock valued at $2,560,000 after acquiring an additional 65,449 shares during the period. Quantbot Technologies LP boosted its stake in Astrana Health by 152.5% in the fourth quarter. Quantbot Technologies LP now owns 10,651 shares of the company's stock valued at $336,000 after acquiring an additional 6,433 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Astrana Health in the fourth quarter valued at approximately $318,000. Finally, Vanguard Group Inc. boosted its stake in Astrana Health by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 4,685,959 shares of the company's stock valued at $147,748,000 after acquiring an additional 20,757 shares during the period. 52.77% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, Barclays started coverage on Astrana Health in a research note on Tuesday, April 1st. They issued an "equal weight" rating and a $36.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $53.29.
View Our Latest Stock Analysis on Astrana Health
Astrana Health Stock Performance
ASTH stock traded up $0.77 during mid-day trading on Friday, reaching $23.27. 296,000 shares of the stock traded hands, compared to its average volume of 277,934. The company has a quick ratio of 1.70, a current ratio of 1.70 and a debt-to-equity ratio of 0.54. The business has a 50-day moving average of $24.82 and a two-hundred day moving average of $29.85. Astrana Health, Inc. has a 52 week low of $22.45 and a 52 week high of $63.20. The firm has a market capitalization of $1.30 billion, a PE ratio of 32.32, a P/E/G ratio of 0.83 and a beta of 0.84.
Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.09). The business had revenue of $620.39 million during the quarter, compared to analyst estimates of $628.11 million. Astrana Health had a return on equity of 4.90% and a net margin of 1.56%. The business's revenue for the quarter was up 53.4% on a year-over-year basis. During the same period last year, the company earned $0.31 EPS. As a group, equities analysts predict that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.
Astrana Health Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Recommended Stories

Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.